INTRODUCTION

Here, we report a case of PNH with gastroduodenal lesions likely caused by transient mucosal ischemia due to thrombosis. When patients with PNH present with abdominal symptoms, thrombosis-induced gastrointestinal injury should be considered. Recognition of gastric patchy redness on esophagogastroduodenoscopy may help make the diagnosis of this potentially serious complication.

Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder that is characterized by hemolytic anemia, bone marrow failure, and thrombosis.1 Thromboembolism in PNH is associated with poor prognosis and is a leading cause of death.2,3 Making prompt diagnosis of thrombosis is important to help determine the treatment for patients with PNH.4 However, making the diagnosis is sometimes challenging, partly because of caregivers’ unfamiliarity with its clinical manifestations. Despite the high frequency of intraabdominal thrombosis in PNH,2 reports of upper gastrointestinal manifestations of thrombotic complications are rare.5 Here, we report a patient with PNH who developed gastric and duodenal lesions likely caused by transient mucosal ischemia due to PNH-related thrombosis. This case report was prepared according to the CARE Guidelines.6

CASE REPORT

A 64-year-old woman presented to the emergency department with fever and dark urine of one week’s duration. Two years earlier, PNH was diagnosed, based on flow cytometry findings of peripheral blood. Although thrombocytopenia had been present, no specific therapy was necessary. Her past medical history included hyperlipidemia and Helicobacter pylori–induced gastritis; H pylori had been eradicated. She had a temperature of 38.2°C and tenderness in the left costovertebral angle. Laboratory tests revealed severe anemia, thrombocytopenia, and coagulopathy (Table 1). C-reactive protein was 33.2 mg/dL [normal range, 0.00-0.14], lactate dehydrogenase 802 U/L [124-222], and serum creatinine 3.81 mg/dL [0.46-0.79]. Blood and urine cultures were negative, probably because she had taken oral antibiotics before...
presentation. Bacterial infection–triggered hemolysis, possibly from pyelonephritis, was suspected.

She was admitted, and we started intravenous administration of prednisolone, lansoprazole, and ceftriaxone (Figure 1). Blood products, including haptoglobin, were also given. Two days later, hematologic and inflammatory markers improved; however, she developed upper abdominal pain and vomiting. Computed tomography (CT) revealed marked thickening of the duodenal wall (Figure 2). Esophagogastroduodenoscopy (EGD) revealed patchy redness of the gastric mucosa (Figure 3A) and a large punched-out ulcer in the duodenum (Figure 3B), with clear demarcation between normal and affected mucosa. Biopsy specimens had no specific findings—malignant cells, granuloma, nor viral inclusion bodies. Thus, we suspected transient ischemia due to PNH-related thrombosis had caused the gastroduodenal injury.

Because there were no signs suggestive of bowel obstruction, perforation, or uncontrolled bleeding, we continued therapy for PNH, with corticosteroids, proton-pump inhibitor, and diet control. Her symptoms improved in a few days.

In a follow-up EGD performed 3 weeks after admission, the gastric patchy redness had disappeared, and the duodenal ulcer had improved (Figure 4). In laboratory tests, fibrin-related markers also normalized (Table 1). After vaccination against meningococcus, eculizumab was added to the therapy to achieve better control of the PNH.

3 | DISCUSSION

To our best knowledge, this is the first report of endoscopic findings of gastric lesions likely caused by PNH-related thrombosis; patchy areas of gastric redness were the distinctive features. We hope this report will help clinicians recognize and manage the rare but potentially serious gastrointestinal complications of PNH.

Making the diagnosis of PNH-related thrombosis can be challenging, mainly because of unfamiliarity with this rare complication. In our patient, the cause of the gastroduodenal lesions in our patient was initially unexplained: H pylori had been eradicated; she used nonsteroidal anti-inflammatory drugs (NSAIDs) only occasionally; she did not take antithrombotic drugs; and she had no abnormal laboratory tests or past history or family history suggesting other gastrointestinal diseases, for example, inflammatory bowel diseases, autoimmune vasculitis, or viral infection. In addition, endoscopic biopsy did not show any disease-specific findings. She had received prednisolone before endoscopic examination for a few days, but steroids were known to be a high risk of peptic ulcer disease when used together with NSAIDs or for more than a month.7,8 The single and short-term use of prednisolone was not likely to be a cause for ulcers in our case.

PNH-related thrombosis is rarely encountered in Japan. The prevalence of PNH is 6.93 per million population,9 and PNH-related thrombosis is reported in only 4.3% of PNH patients in Japan.10 On the other hand, about half of PNH patients in Western countries die from thrombotic complications11; this regional difference is unexplained. Nonetheless, thromboembolic complications are a significant cause of death in PNH. Hemolysis and elevation of D-dimer levels, noted in our patient, are known as the signs of thrombotic complications.4,12 In addition, in PNH-related thrombosis, intraabdominal veins are most often involved.13 Thus, thrombotic gastrointestinal injury should be suspected in patients with PNH presenting with such laboratory findings and gastrointestinal symptoms.

Clinical manifestations and endoscopic findings of PNH-related upper gastrointestinal lesions are not well known. As far as we know, only six case reports have been published5,14-18; their salient findings are summarized in Table 2. According to those reports, any portion of the duodenum was affected, the small bowel was frequently involved simultaneously, and surgical treatment was

| TABLE 1 | Laboratory data before and after treatment |
|-----------------|-----------------|-----------------|
|                | Normal range    | At admission    | 3 weeks later |
| Hb (g/dL)      | 11.6-14.8       | 4.5             | 7.5           |
| WBC (/μL)      | 3300-8600       | 12 400          | 4600          |
| PLT (×10^3/μL) | 16.0-36.0       | 1.5             | 4.2           |
| PT-INR         | 0.91-1.14       | 1.21            | 1.00          |
| APTT (s)       | 26.9-38.1       | 27.4            | <20.0         |
| FDP (μg/mL)    | 0.0-5.0         | 81.3            | 3.1           |
| D-dimer (μg/mL)| 0.0-1.0         | 35.0            | 1.0           |
| Haptoglobin (mg/dL) | 19.0-170.0 | <1.0            | 2.0           |

Abbreviations: APTT, activated partial thromboplastin time; FDP, fibrinogen degradation products; Hb, hemoglobin; PLT, platelet count; PT-INR, prothrombin time-international normalized ratio; WBC, white blood cell.

FIGURE 1 Clinical course. CT, computed tomography; EGD, esophagogastroduodenoscopy; Hb, hemoglobin; Hp, haptoglobin; PC, platelet concentrate; PLT, platelet count; PPI, proton-pump inhibitor; PSL, prednisolone; RBCs, red blood cells
sometimes required. Pathologically, intravenous thrombosis, vascular proliferation, and papillary endothelial hyperplasia within the duodenal submucosa have been reported\(^{14-17}\); a characteristic CT finding is edematous thickening of the duodenal wall.\(^5\,\text{15-17}\) Among EGD findings, various degrees of erosion and/or ulceration with clear demarcation have been described.\(^5\,\text{14-17}\) The patchy areas of gastric redness present in our patient have not been reported so far. It seems difficult to make a diagnosis of PNH by endoscopic biopsy; nonetheless, gastrointestinal biopsy may be beneficial in differentiating PNH from IgA vasculitis, which can present with both gastric patchy redness and duodenal ulcer.\(^{19,20}\)

Treatment with corticosteroids, proton-pump inhibitors, and diet control was successful in our patient. Various treatments have been reported for PNH-related thrombosis.\(^2\) In cases of bowel obstruction or perforation, surgical treatment has been needed\(^{17,18}\); in cases without such complication, nonoperative therapy was appropriate.\(^21\) In patients with life-threatening thrombosis, anticoagulation therapy is necessary. In Japan, however, PNH patients die from bleeding events more often than from thrombotic complication.\(^10\) Thus, we avoided anticoagulation therapy. Eculizumab is another treatment option\(^2,22\); however, at least two weeks after vaccination against \textit{Neisseria meningitides} are required before initiation of eculizumab. We used corticosteroids, expecting a rapid suppression of hemolysis,\(^23\) but its effect on thrombosis was unclear. Fortunately, corticosteroid therapy together with proton-pump inhibitor and diet control was adequate in our case. In the absence of definitive treatment, early and accurate diagnosis of thrombotic complications seems important so the thrombotic manifestations can be treated and surgical intervention avoided.

In conclusion, in patients with PNH who have abdominal symptoms, gastrointestinal injury caused by PNH-related thrombosis should be suspected. In addition to laboratory
data suggesting thrombosis, recognition of gastric patchy redness at EGD may help reach the diagnosis of this potentially serious complication of PNH.

ACKNOWLEDGMENTS
The authors would like to thank William R Brown, MD (the Director of International Medical Editing Service), for the English language review. Published with written consent of the patient.

CONFLICT OF INTEREST
The authors declare no conflicts of interest associated with this manuscript.

AUTHOR CONTRIBUTIONS
MU, KO, and RT: involved in the patient’s care. MU and YS: contributed to the conception of the work. MU: drafted the manuscript. YS, KO, RT, HY, and MM: revised the manuscript. All authors: discussed the clinical case, interpreted the findings, and contributed to the final manuscript.

ETHICAL APPROVAL
Informed consent was obtained from the patient for publication of this case report and accompanying images.

DATA AVAILABILITY STATEMENT
Nondigital data available.

ORCID
Masayuki Ueno https://orcid.org/0000-0002-2497-9327

REFERENCES
1. Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124:2804-2811.
2. Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121:4985-5105.
3. Socié G, Mary J-Y, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348:573-577.
4. Sahin F, Akay OM, Ayer M, et al. Pesg PNH diagnosis, follow-up and treatment guidelines. Am J Blood Res. 2016;6:19-27.
5. Torres J, De Vroey B, Noël MP, Notteghem B, Colombel JF. Recurrent small bowel ischemia in a patient with paroxysmal nocturnal hemoglobinuria. Nat Rev Gastroenterol Hepatol. 2010;7:410-414.
6. Gagnier JJ, Kienle G, Altman DG, et al. The CARE guidelines: consensus-based clinical case report guideline development. J Clin Epidemiol. 2014;67:46-51.
7. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114:735-740.
8. Guslandi M. Steroid ulcers: any news? World J Gastrointest Pharmacol Ther. 2013;4:39-40.
9. Le XF, Yang TY, Yang XY, Wang XM. Characteristics of paroxysmal nocturnal hemoglobinuria in China. Clinical analysis of 476 cases. Chin Med J. 1990;103:885-889.
10. Nishimura J-I, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83:193-207.
11. Devalet B, Mullier F, Chatelain B, Dogné JM, Chatelain C. Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review. Eur J Haematol. 2015;95:190-198.
12. Hugel B, Socié G, Vu T, et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood. 1999;93:3451-3456.
13. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253-1258.
14. Dunphy CH, Sotel-Avila C, Luisiri A, Chu JY. Paroxysmal nocturnal hemoglobinuria associated with venous thrombosis and...
papillary endothelial hyperplasia presenting as ulcerated duodenal mass. *Arch Pathol Lab Med*. 1994;118:837-839.

15. Zapata R, Mella JG, Rollán A. Intestinal ischemia complicating paroxysmal nocturnal hemoglobinuria. *Gastrointest Endosc*. 1998;47:184-186.

16. Adams T, Fleischer D, Marino G, Rusnock E, Li L. Gastrointestinal involvement in paroxysmal nocturnal hemoglobinuria: first report of electron microscopic findings. *Dig Dis Sci*. 2002;47:58-64.

17. Quentin V, Dinasquet M, Rioux-Leclercq N, et al. Paroxysmal nocturnal hemoglobinuria associated with intestinal ischemia leading to small bowel perforation. *Gastroenterol Clin Biol*. 2003;27:927-931.

18. Tezcaner T, Ekici Y, Kırnap M, Kural F, Moray G. Delayed duodenal obstruction after intramural hematoma in a patient with paroxysmal nocturnal hemoglobinuria: a case report. *Int J Surg Case Rep*. 2014;5:605-607.

19. Ebert EC. Gastrointestinal manifestations of Henoch-Schonlein Purpura. *Dig Dis Sci*. 2008;53:2011-2019.

20. Kawasaki K, Nakamura S, Esaki M, et al. Gastrointestinal involvement in patients with vasculitis: IgA vasculitis and eosinophilic granulomatosis with polyangiitis. *Endosc Int Open*. 2019;7:E1333-E1343.

21. Bruaasd L, Antunes L, Collinet-Adler S, et al. Acute mesenteric venous thrombosis: case for nonoperative management. *J Vasc Surg*. 2001;34:673-679.

22. Parker CJ. Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy. *Hematology Am Soc Hematol Educ Program*. 2011;2011:21-29.

23. Rosse WF. Treatment of paroxysmal nocturnal hemoglobinuria. *Blood*. 1982;60:20-23.

How to cite this article: Ueno M, Shimodate Y, Okada K, Takaya R, Yamamoto H, Mizuno M. Upper gastrointestinal ischemia as a rare complication of paroxysmal nocturnal hemoglobinuria. *Clin Case Rep*. 2021;9:506–510. https://doi.org/10.1002/ccr3.3567